Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model-Reference-Cited by-同舟云学术

Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model

Published:2022-09-20 Issue:9 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Islam Kamrul¹^ORCID,Sime Fekade B.¹^ORCID,Wallis Steven C.¹,Bauer Michelle J.¹,Naicker Saiyuri¹,Won Hayoung¹,Zowawi Hosam M.¹,Choudhury Md Abu²,Shirin Tahmina³,Habib Zakir H.³,Harris Patrick N. A.¹⁴⁵^ORCID,Flora Meerjady S.⁶,Roberts Jason A.¹⁴⁷⁸^ORCID

Affiliation:

1. University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia

2. School of Nursing, Midwifery & Public Health, University of Canberra, Bruce, Australian Capital Territory, Australia

3. Institute of Epidemiology, Disease Control and Research, Mohakhali, Dhaka, Bangladesh

4. Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Queensland, Australia

5. Pathology Queensland, Royal Brisbane and Women’s Hospital, Herston, Queensland, Australia

6. Directorate General of Health Services, Mohakhali, Dhaka, Bangladesh

7. Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia

8. Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, Nîmes, France

Abstract

Carbapenems are recommended for the treatment of urosepsis caused by extended-spectrum β-lactamase (ESBL)-producing, multidrug-resistant Escherichia coli ; however, due to selection of carbapenem resistance, there is an increasing interest in alternative treatment regimens including the use of β-lactam-aminoglycoside combinations. We compared the pharmacodynamic activity of piperacillin-tazobactam and amikacin as mono and combination therapy versus meropenem monotherapy against extended-spectrum β-lactamase (ESBL)-producing, piperacillin-tazobactam resistant E. coli using a dynamic hollow fiber infection model (HFIM) over 7 days.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00162-22

Reference53 articles.

1. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

2. Urosepsis: Overview of the Diagnostic and Treatment Challenges

3. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study

4. Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis

5. Condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harvesting and amplifying gene cassettes confers cross-resistance to critically important antibiotics;2023-12-04

2. Antimicrobial Multidrug Resistance: Clinical Implications for Infection Management in Critically Ill Patients;Microorganisms;2023-10-16

3. Guanidinylated Amphiphilic Tobramycin Derivatives Synergize with β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa;ACS Infectious Diseases;2023-08-21

4. Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model againstKlebsiella pneumoniae—authors’ response;Journal of Antimicrobial Chemotherapy;2023-01-30